Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab

NCT03257163 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT03257163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03257163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 29, 2017
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus positive, gastric adenocarcinoma, mismatch repair protein deficiency, stage ib gastric cancer ajcc v7, stage ii gastric cancer ajcc v7, stage iia gastric cancer ajcc v7, stage iib gastric cancer ajcc v7, stage iii gastric cancer ajcc v7, stage iiia gastric cancer ajcc v7, stage iiib gastric cancer ajcc v7, stage iiic gastric cancer ajcc v7